Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR. - Suppr | 超能文献

Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR.

作者信息

Egan Marie E

机构信息

1 Department of Pediatrics and.

2 Department of Cellular and Molecular Physiology Yale School of Medicine New Haven, Connecticut.

出版信息

Am J Respir Crit Care Med. 2017 Apr 1;195(7):849-850. doi: 10.1164/rccm.201611-2290ED.

DOI:10.1164/rccm.201611-2290ED

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Effects of Lumacaftor/Ivacaftor in a Pediatric Cohort Homozygous for F508del-CFTR.

Am J Respir Crit Care Med. 2017 Apr 1;195(7):849-850. doi: 10.1164/rccm.201611-2290ED.

2

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.在 F508del-CFTR 纯合子的 6-11 岁囊性纤维化患者中， lumacaftor 和 ivacaftor 的疗效和安全性：一项随机、安慰剂对照的 3 期临床试验。

Lancet Respir Med. 2017 Jul;5(7):557-567. doi: 10.1016/S2213-2600(17)30215-1. Epub 2017 Jun 9.

3

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.评估长期使用组合 Lumacaftor 和 Ivacaftor 疗法治疗囊性纤维化纯合子 F508del-CFTR 突变患者的安全性和疗效（PROGRESS）：一项 3 期扩展研究。

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

4

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.鲁马卡托-依伐卡托用于携带苯丙氨酸508位缺失CFTR基因纯合突变的囊性纤维化患者。

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

5

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Lumacaftor/Ivacaftor：囊性纤维化治疗药物。

Drugs. 2016 Aug;76(12):1191-201. doi: 10.1007/s40265-016-0611-2.

6

Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.鲁马卡托单独使用及与依伐卡托联合使用：F508del囊性纤维化跨膜传导调节因子校正的临床前及临床试验经验

Expert Rev Respir Med. 2016;10(1):5-17. doi: 10.1586/17476348.2016.1122527. Epub 2015 Dec 9.

7

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.鲁马卡托-依伐卡托用于携带苯丙氨酸508缺失（Phe508del）囊性纤维化跨膜传导调节因子（CFTR）纯合突变的囊性纤维化患者

N Engl J Med. 2015 Oct 29;373(18):1783. doi: 10.1056/NEJMc1510466.

8

An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.一项观察性研究：在开始使用 Lumacaftor/Ivacaftor 的囊性纤维化患者中的结局和耐受性。

Ann Am Thorac Soc. 2017 Nov;14(11):1662-1666. doi: 10.1513/AnnalsATS.201701-058OC.

9

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.鲁马卡托/依伐卡托治疗F508del-CFTR杂合型囊性纤维化患者

Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.

10

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.针对携带Phe508del CFTR纯合突变的囊性纤维化患者使用鲁马卡托-依伐卡托。

N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466.

引用本文的文献

1

Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.Src 激酶抑制可减少 ΔF508 人胆管细胞的炎症和细胞骨架变化，并提高囊性纤维化跨膜电导调节剂纠正剂的疗效。

Hepatology. 2018 Mar;67(3):972-988. doi: 10.1002/hep.29400. Epub 2018 Jan 26.